First, Know Thyself: A Self-Assessment Program on Management of IBD

The Gastroenterology Learning Pathway
0.5 AMA PRA Category 1 Credit(s)
Launch Date:
September 15, 2016
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Gastroenterologists and gastroenterology clinicians

Relevant Terms:

IBD Management

David T. Rubin, MD, AGAF, FACG, AGAF, FACP

David T. Rubin, MD, AGAF, FACG, AGAF, FACP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

David T. Rubin graduated with honors from the University of Chicago Pritzker School of Medicine and completed his internship, residency, and fellowships in both gastroenterology and clinical medical ethics at the University of Chicago.
He is the Joseph B. Kirsner Professor of Medicine; chief of the Section of Gastroenterology, Hepatology, and Nutrition; and codirector of the Digestive Diseases Center at the University of Chicago Medicine. Dr. Rubin previously served for 11 years as director of the Gastroenterology, Hepatology, and Nutrition fellowship program. He also is an associate faculty member at the Maclean Center for Clinical Medical Ethics and an associate investigator at the University of Chicago Comprehensive Cancer Center.
Dr. Rubin is the editor of a best-selling book on inflammatory bowel disease (IBD), now in its second edition, and an author or co-author of many peer-reviewed articles on IBD, virtual colonoscopy, genetic testing in IBD, and cancer in IBD. He is also a featured media contact for issues related to IBD, appearing on satellite radio, on television, and in print media. His principal research interests include novel IBD therapies and outcomes, colon cancer prevention, and clinical medical ethics.
Dr. Rubin is a fellow of the American Gastroenterological Association, American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy, and American College of Physicians, and he is an active national member of the Crohn’s & Colitis Foundation of America and is on the Board of Trustees for the ACG. Chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology), he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), the Cancer Research Foundation Young Investigator’s Award (2004), and the University of Chicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, Dr. Rubin received CCFA's Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families.
1. Compare and contrast the clinical effects of inflammatory bowel disease (IBD) therapies
2. Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity
3. Utilize available disease progression and drug monitoring strategies for patients with IBD
4. Implement American Gastroenterological Association (AGA) practice measures in managing patients with IBD

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • David T. Rubin, MD, has affiliations with Consulting: AbbVie, Amgen, Emmi, Genentech, Janssen, Pfizer, Shire, Takeda, UCB Pharma; Grant Support: AbbVie, Genentech, Janssen, Prometheus Laboratories, Shire, Takeda, UCB Pharma; Co-Founder: Cornerstones Health (nonprofit medical education entity); Board of Trustees: American College of Gastroenterology; Co-Founder: GoDuRn, LLC.
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests to disclose.
  • Kyra Sheahan has no affiliations with commercial interests to disclose.
AGA Institute
  • Sandra Megally has no affiliations with commercial interests to disclose.
  • Maura H. Davis has no affiliations with commercial interests to disclose.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 0.5 hours
Medium: Internet

There is no fee for this educational activity.

This activity is supported by independent educational grants from AbbVie, Shire, and Takeda Pharmaceuticals, USA, Inc.

By reviewing the course content and successfully completing the post-test and evaluation, physicians, physician assistants, and nurse practitioners are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
Physicians, physician assistants, and nurse practitioners who successfully complete the post-test and evaluation will receive CME credit. Users must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above